Rheumatoid Arthritis: Assessment Tools & Current Treatment Strategies

Rheumatoid arthritis is a chronic inflammatory disorder mainly involving joints. It is a lifelong process &its etiology is poorly understood.It is the result of interaction between the environmental factors with the genetics of persons which is likely to associated with the disease. Many assessment tools have been used for assessing the disease with each having its own merits & demerits. For its treatment patient has to take medicines for life long which results in tolerance to efficacy & increase in adverse effects. Different treatment guidelines are followed in different parts of world according to their convenience. No doubt drugs like methotrexate, hydroxychloroquine, leflunamide, sulfasalazine are still the pillars of the treatment but there is always a need for newer efficacious & safe drugs for the treatment of rheumatoid arthritis. © 2011 IGJPS. All rights reserved.

• Publication year

  2013

• Venue

  Indo global journal of pharmaceutical sciences

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.35652/igjps.2013.09
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Harrison's principle of internal medicine

  2012cited by this paper
• Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus

  2010cited by this paper
• UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha,

  2010cited by this paper
• Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

  2010influential reference
• Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population.

  2009cited by this paper
• EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

  2009cited by this paper
• Environmental influences on risk for rheumatoid arthritis

  2009cited by this paper
• Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

  2008cited by this paper
• Evidence that cytokines play a role in rheumatoid arthritis.

  2008cited by this paper
• Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

  2008cited by this paper
• The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture.

  2008cited by this paper
• Ocular Toxicity of Hydroxychloroquine

  2008cited by this paper
• Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

  2008cited by this paper
• Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

  2008influential reference
• Neuroendocrine–immune interactions in synovitis

  2007cited by this paper
• Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.

  2007cited by this paper
• Early rheumatoid arthritis.

  2007cited by this paper
• New concepts in antimalarial use and mode of action in dermatology

  2007cited by this paper
• Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management.

  2007cited by this paper
• Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

  2007cited by this paper
• The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care.

  2007cited by this paper
• Hydroxychloroquine-induced toxic myopathy causing respiratory failure.

  2007cited by this paper
• 5‐Aminosalicylates and renal function in inflammatory bowel disease: A systematic review

  2007cited by this paper
• Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs

  2007cited by this paper
• The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

  2006cited by this paper
• FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke

  2005cited by this paper
• Leflunomide induced acute interstitial pneumonia.

  2005cited by this paper
• Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.

  2005cited by this paper
• Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.

  2004cited by this paper
• Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests

  2004cited by this paper
• Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

  2004cited by this paper
• The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.

  2004cited by this paper
• The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.

  2004cited by this paper
• Kelley's Textbook of Rheumatology

  2004cited by this paper
• Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

  2003cited by this paper
• Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

  2003cited by this paper
• Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

  2003cited by this paper
• A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

  2003cited by this paper
• A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs.

  2002cited by this paper
• Guidelines for the Management of Rheumatoid Arthritis

  2002cited by this paper
• Pneumocystis carinii pneumonia associated with leflunomide therapy for rheumatoid arthritis.

  2002cited by this paper
• Cyclooxygenase-2 inhibition and cardiovascular events.

  2002cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002influential reference
• Guidelines for the management of rheumatoid arthritis: 2002 update.

  2002cited by this paper
• Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.

  2001cited by this paper
• Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia

  2001cited by this paper
• Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy.

  2001cited by this paper
• Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis.

  2000cited by this paper
• Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.

  2000cited by this paper
• The changing face of rheumatoid arthritis therapy: results of serial surveys.

  2000influential reference
• Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid.

  1999cited by this paper
• Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.

  1999cited by this paper
• American College of Rheumatology

  1999cited by this paper
• Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans*

  1998cited by this paper
• Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

  1998cited by this paper
• The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

  1995cited by this paper
• Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

  1995influential reference
• Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.

  1995cited by this paper
• Tetracyclines may be therapeutically beneficial in rheumatoid arthritis.

  1995cited by this paper
• Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis

  1995cited by this paper
• Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity.

  1995cited by this paper
• Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial.

  1994influential reference
• Minocycline in Active Rheumatoid Arthritis

  1994cited by this paper
• Current Medical Diagnosis & Treatment

  1993cited by this paper
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

  1993cited by this paper
• Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.

  1993cited by this paper
• Development of a disease activity score based on judgment in clinical practice by rheumatologists.

  1993cited by this paper
• Development of a disease activity score based on judgment in clinical practice by rheumatologists.

  1993cited by this paper
• Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids.

  1990cited by this paper
• Risk of infectious complications in patients taking glucocorticosteroids.

  1989cited by this paper
• The measurement of pain.

  1988cited by this paper
• [Rheumatoid arthritis].

  1983cited by this paper
• Basic and Clinical Pharmacology

  1982cited by this paper
• Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells.

  1982cited by this paper
• Effect of antimicrobial agents on human polymorphonuclear leukocyte microbicidal function

  1981cited by this paper
• An assessment of grip strength measurement in rheumatoid arthritis.

  1974cited by this paper
• Pharmacokinetic studies on minocycline in man

  1973cited by this paper
• Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

  1973cited by this paper
• Measurement in rheumatoid arthritis.

  1972cited by this paper
• The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

  1972cited by this paper
• [Etiology and pathogenesis of rheumatoid arthritis. I. ].

  1956cited by this paper
• American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

  year unknowncited by this paper

• No citing papers are available for this paper.